AstraZeneca and Bristol Myers Squibb (BMS) have reportedly held preliminary discussions around a potential combination that could create one of the world’s largest pharmaceutical companies, with a combined market value of close to $400bn.
The talks, which were first reported by the Financial Times, remain at an early stage and could ultimately be delayed or abandoned. Neither company has confirmed that a transaction is being pursued.
A deal would have significant implications for the pharma manufacturing sector.
The combined group would bring together two major global supply networks, including manufacturing, development and distribution capabilities across the US and Europe.
US manufacturing in focus
The potential transaction also comes as AstraZeneca is already expanding its US manufacturing footprint.
In 2025, the company announced plans to invest $50bn in US medicines manufacturing and R&D by 2030, including a new multi-billion-dollar drug substance manufacturing facility in Virginia focused on chronic disease medicines.
The programme also includes expansions across Maryland, Massachusetts, California, Indiana and Texas.
AstraZeneca has said the investment supports its ambition to generate $80bn in annual revenue by 2030, with around half expected to come from the US.
The company also previously committed $3.5bn to expand its US research and manufacturing footprint by the end of 2026.
BMS, meanwhile, operates manufacturing facilities across multiple regions, including biologics production in Manatí, Puerto Rico, cell therapy manufacturing in Bothell, Washington and commercial manufacturing operations in Switzerland.
Its UK Moreton site supports product development, supply and distribution and was expanded in 2025.
Oncology overlap raises issues
Both companies' substantial oncology businesses could prove a major obstacle to any transaction.
BMS generated $10bn in 2025 revenue from its Opdivo cancer therapy, while AstraZeneca’s oncology portfolio includes competing immunotherapies such as Imfinzi.
Any merger would therefore face substantial antitrust scrutiny — particularly in the US.
The FTC has continued to require divestitures in pharmaceutical transactions where consolidation could reduce competition; for example, Aurobindo Pharma’s $250m acquisition of Lannett.
Aurobindo's purchase was approved on the condition that it divested four generic drug products: mycophenolate mofetil, pilocarpine, rabeprazole and another overlapping product.
These were sold to Quagen Pharmaceuticals to address the anticompetitive concerns.
Implications of a deal
For manufacturers in the pharma sector, this new combination could bring opportunities for network rationalisation, technology transfer and supply-chain consolidation, but could also result in significant restructuring across overlapping production and development infrastructure.
With no deal agreed yet, the immediate manufacturing impact remains uncertain, but the talks underline the growing strategic importance of US-based pharmaceutical manufacturing as major drugmakers aim to strengthen domestic supply chains and expand their presence in the world’s largest medicines market.
